Sugi Predict

Sugi Predict / Targets / TNFRSF1A

TNFRSF1A

Tumor necrosis factor receptor superfamily member 1A · P19438 · TNFRSF1A on Sugi Atlas →

28,714 patent compounds predicted against TNFRSF1A, 20,697 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL111283 SCHEMBL111283 0.46 8/20
SCHEMBL615819 SCHEMBL615819 0.76 5/20
SCHEMBL679431 SCHEMBL679431 0.59 5/20
Roletamide Roletamide (SCHEMBL115771) 0.56 5/20
SCHEMBL112596 SCHEMBL112596 0.38 5/20
SCHEMBL783240 SCHEMBL783240 0.57 4/20
SCHEMBL805335 SCHEMBL805335 0.57 4/20
SCHEMBL503154 SCHEMBL503154 0.53 4/20
SCHEMBL503155 SCHEMBL503155 0.53 4/20
SCHEMBL177152 SCHEMBL177152 0.52 4/20
SCHEMBL177153 SCHEMBL177153 0.52 4/20
SCHEMBL633909 SCHEMBL633909 0.72 3/20
SCHEMBL633910 SCHEMBL633910 0.72 3/20
SCHEMBL622882 SCHEMBL622882 0.61 3/20
SCHEMBL622883 SCHEMBL622883 0.61 3/20
SCHEMBL622884 SCHEMBL622884 0.61 3/20
SCHEMBL374153 SCHEMBL374153 0.57 3/20
SCHEMBL524712 SCHEMBL524712 0.56 3/20
SCHEMBL527576 SCHEMBL527576 0.56 3/20
SCHEMBL662265 SCHEMBL662265 0.53 3/20

Clinical trials — most relevant to TNFRSF1A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) PHASE4COMPLETED
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes PHASE4COMPLETED
Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) PHASE2COMPLETED
Etanercept in Hidradenitis Suppurativa PHASE2COMPLETED
FITMI - First In Treating Male Infertility PHASE2ACTIVE_NOT_RECRUITING
NAPO - Novel Approach for Oligospermia PHASE1/PHASE2COMPLETED
TNFSF11 Inhibition and Fertility: a Prospective Study PHASE2COMPLETED
Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction PHASE2COMPLETED
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis PHASE2COMPLETED
NT-NOA - Novel Treatment of Some Men With Non-Obstructive Azoospermia PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions) PHASE2COMPLETED
Phase 1 Dose Escalation Study of Intra-Articular Administration of tgAAC94 PHASE1COMPLETED
Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein PHASE1COMPLETED
Presurgical Trial of Denosumab in Breast Cancer EARLY_PHASE1COMPLETED
Evaluation of Salivary Biomarker Levels in Individuals With Different Periodontal Conditions nanCOMPLETED
TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP) nanNOT_YET_RECRUITING
Er,Cr:YSGG Laser Application in Peri-implantitis nanCOMPLETED
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection nanRECRUITING
Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers nanUNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Functional Implications of TNF nanCOMPLETED
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer nanUNKNOWN
Point of Care Test of LTA Level in Tear Fluid, Measured With a POCT Test, in DE Patients Following IPL Treatment nanUNKNOWN
Effect of Smoking on Periodontal Therapy in Periodontitis nanCOMPLETED
The Impact of Targeted Therapy on Microorganism in Patients With Psoriasis nanUNKNOWN
Dcr3 Levels in Blood and Urine on Renal and Patient Prognosis in Patients With Acute Kidney Injury nanUNKNOWN
NCF Gene & TNFSF4 in SLE Patients nanUNKNOWN
Multiple Sclerosis nanUNKNOWN
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a TNFRSF1A binder may also engage these)

ProteinNameSimilarity
P50555 — 1.000 P50555 →
O19131 — 0.999 O19131 →
P25118 — 0.985 P25118 →
P41272 — 0.977 P41272 →
P22934 — 0.976 P22934 →
P07174 — 0.972 P07174 →
Q92956 — 0.971 Q92956 →
Q8BX43 — 0.971 Q8BX43 →
P26842 — 0.970 P26842 →
P18519 — 0.969 P18519 →
Q6UX15 — 0.969 Q6UX15 →
Q96MU8 — 0.969 Q96MU8 →
NGFR Tumor necrosis factor receptor superfamily member 16 0.968 landscape →
Q93038 — 0.968 Q93038 →
Q9Z0W1 — 0.968 Q9Z0W1 →
Q6AZ51 — 0.968 Q6AZ51 →
Q9UNE0 — 0.967 Q9UNE0 →
Q9R187 — 0.967 Q9R187 →
Q8NFR9 — 0.966 Q8NFR9 →
P38484 — 0.966 P38484 →
Q9Z209 — 0.966 Q9Z209 →
Q9N092 — 0.966 Q9N092 →
PML Protein PML 0.966 landscape →
Q68US5 — 0.966 Q68US5 →
Q60953 — 0.965 Q60953 →
Q5T848 — 0.965 Q5T848 →
Q924S4 — 0.965 Q924S4 →
Q75VT8 — 0.964 Q75VT8 →
P22273 — 0.964 P22273 →
Q3ZTK5 — 0.964 Q3ZTK5 →